Biogen Inc.'s latest quarterly earnings report is set for Tuesday, April 28th, with a consensus estimate EPS of 2.96.
In today's trading session, Biogen Inc. (BIIB) is priced at $183.24, marking a $2.57 increase (1.42%) from the previous close. Trading volume stands at $147,449, representing an 11.92% increase relative to the average.
BIIB has seen a three-day streak with a price decrease of $6.83 (-3.59%) since starting at $190.07.
The most recent earnings report, dated Thursday, February 5th, indicated a consensus estimate EPS of 1.66.
The company experienced a net change in cash of -$856.6 million, ending the period with $3 billion in cash.
Biogen Inc. reported a net loss of $48.41 million, with revenue totaling $2.28 billion and a gross profit of $1.78 billion.
Key ratios include a gross profit margin of 78.23%, return on equity of -0.27, and a price to sales ratio of 11.33.
The balance sheet shows total assets of $29.44 billion, total liabilities of $11.18 billion, and net debt of $3.94 billion.
This real-time report provides insights into Biogen Inc.'s recent performance, upcoming earnings, and financial position, shaping expectations for investors and analysts alike.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.